Callentis Consulting Group LLC

Callentis Consulting Group LLC, a woman-owned small business based in Austin, Texas, operates as a prime recipient of federal research and development funding focused on transportation infrastructure innovation and biomedical R&D, with a secondary grant sub-recipient relationship. The vendor holds WOSB (women-owned small business) designation and competes primarily under total small business set-aside authority across Department of Transportation and National Institutes of Health programs.

Callentis's federal footprint is concentrated in SBIR Phase contracts and NIH research grants. On the transportation side, the vendor has executed a multi-phase SBIR effort with the Department of Transportation's Immediate Office of the Secretary addressing in-situ determination of pore solution resistivity—a Phase I contract awarded in June 2021, a Phase II ($998,361) awarded June 27, 2022 with ultimate completion September 26, 2024, and a Phase IIB ($498,577) awarded July 22, 2026 running through July 21, 2028. On the biomedical side, Callentis received a $1.1 million equivalent NIH research grant from the National Institute on Drug Abuse (awarded May 1, 2025, completing April 30, 2027) for an AI platform to discover therapeutics for substance use disorders using machine learning and graph neural network models to identify drug targets and candidate compounds; and a grant from the National Institute of Dental and Craniofacial Research (awarded August 19, 2024, completing February 18, 2026) for development of high-performance BPA-free dental restoration composites with remineralization capabilities, executed in partnership with the University of Colorado and New Mexico State University. The vendor also sits as a sub-recipient on a National Academy of Sciences grant awarded March 17, 2026 addressing pavement management through original equipment manufacturer vehicle sensor data.

The vendor has executed six awards total (five as prime recipient or prime contractor, one as sub-recipient) across four distinct federal agencies between June 2021 and July 2026, generating $1.6 million in combined potential value, though cumulative obligation has reached $3.8 million due to Phase continuation funding. Two awards face ultimate completion within the next twenty-four months (combined potential value $499 thousand). SCI-reportable invoiced activity is minimal and dated: $107 thousand in FY2022 across 0.4 FTEs on one prime service contract; no SCI activity recorded in FY2023 or FY2024. The vendor does not operate as a named subcontractor across SCI-reportable service contracts and does not deploy subcontractors on SBIR or grant work in the source data. Transportation R&D and applied research (PSC category) dominate the award portfolio, with secondary life-sciences R&D activity.

Callentis offers federated AI/ML to train models based on large remote data sources or IoT/Edge devices with high efficiency, reliability, privacy, and security. Callentis offers hybrid and physics-informed AI/ML to develop explainable and interpretable models that incorporate both theoretical and experimental/empirical data. Callentis offers AI/MLOps pipelines for deploying practice-ready AI solutions that are continuously updated while being used for inference. Callentis offers practice-ready AI/ML development for prediction, control, optimization, and automation problems that improve productivity, effectiveness, and reliability of business processes. Callentis offers custom Web and Mobile app full-stack and agile software development, UI/UX design and DevOps services. Callentis offers simulation-based design optimization services, leveraging AI tools to increase efficiency of design processes.